title: Nail psoriasis: treatment with tazarotene 0.1% hydrophilic ointment.
abstract: BACKGROUND
  Nail involvement is common in psoriasis and has a considerable impact on patient quality of life. Its clinical presentation depends on which part of the nail is affected: the bed or the matrix. Fifty percent of patients report associated pain. In this study, we analyzed the safety and effectiveness of tazarotene 0.1% in a hydrophilic ointment in the treatment of nail psoriasis.
  
  
  METHODS
  We performed an open observational study of 6 patients diagnosed with nail psoriasis. The patients applied a compounded preparation of tazarotene 0.1% ointment under occlusion every night for 6 months in their homes. They were not receiving any other topical or systemic treatments. Nail psoriasis severity (assessed using the Nail Psoriasis Severity Index [NAPSI]), subungual hyperkeratosis, onycholysis, splinter hemorrhages, oil stains, and nail pitting were evaluated at baseline and at 3 and 6 months.
  
  
  RESULTS
  A statistically significant improvement between baseline and 6 months was observed in all patients: the mean (SD) NAPSI went from 14.3 (6.3; 95% CI, 11.74-16.92) to 2.3 (1.21; 95% CI, 1.84-2.3) while the median went from 15 to 2.5 (P = .007). The percentage improvement at the end of treatment was 87.9%. No adverse effects were observed.
  
  
  CONCLUSIONS
  Our study shows the therapeutic potential of tazarotene ointment in nail psoriasis.
authors: Servicio de Dermatología, Hospital Universitari Sagrat Cor, Barcelona, España. cfischer2@hotmail.com
authors: C
authors: C
authors: Fischer-Levancini
authors: M
authors: M
authors: Sánchez-Regaña
authors: F
authors: F
authors: Llambí
authors: H
authors: H
authors: Collgros
authors: V
authors: V
authors: Expósito-Serrano
authors: P
authors: P
authors: Umbert-Millet
mesh_terms: D003879:Dermatologic Agents / Q000008:administration & dosage*; D006801:Humans; D009260:Nail Diseases / Q000188:drug therapy*; D009539:Nicotinic Acids / Q000008:administration & dosage*; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*; D012176:Retinoids
chemical_list: D003879:Dermatologic Agents; D009539:Nicotinic Acids; D009824:Ointments; C086827:tazarotene; D012176:Retinoids